Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 24, 2010

Amgen Issues Epogen and Procrit Recall

Author(s)Laura Bush

Amgen has issued Epogen and Procrit recall.

Today, Amgen issued a voluntary recall of 201 lots of Epogen and 155 lots of Procrit (epoitin alfa) because of concern about very thin glass flakes in the vials. The flakes, or lamellae, result from the interaction of the formulation with the glass vials over the shelf life of the product.

The company has announced that according to evaluations conducted by Amgen and Centocor, the risk to patients who have received product included in the recall is low. To date, there have been no complaints or adverse events reported which can be directly attributed to the presence of glass lamellae.  

Epogen and Procrit are both manufactured by Amgen. Epogen is sold by Amgen in the United States.  Centocor Ortho Biotech Products is the authorized distributor of Procrit in the United States.

Lists of the recalled product lots and expiration are available at at www.epogen.com and www.procrit.com.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.